

Immutep receives AUD 2.7 million research and development tax incentive from French government

Sydney, Australia, September 23, 2022 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases received a EUR 1,804,341 (AUD 2,693,046) research and development tax incentive payment in, is pleased to announce it has cash from the French Government under its Crédit d'Impôt Recherche scheme (CIR).

The "Crédit d'Impôt Recherche" (CIR), meaning "Research Tax Credit", is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30 percent of their eligible expenditure.

Immutep qualifies to receive the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible research and development activities conducted in the European Union in the 2021 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government's research and development tax incentive program in respect of expenditure incurred on eligible research and development activities conducted in Australia.

The funds will be used to support the ongoing and planned global clinical development of efitlagimod alpha and the preclinical development of IMP761.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is efitlagimod alpha ("efiti" or "IMP321"), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

This announcement has been authorised for release by the Chief Executive Officer, Marc Voigt. Further information can be found on the Company's website www.immutep.com